In a historic shift, the U.S. Drug Enforcement Administration (DEA) is set to reclassify marijuana as a less dangerous drug, marking a significant change in American drug policy. The move, which still requires review by the White House Office of Management and Budget, acknowledges the medical benefits of cannabis and recognizes its lower potential for abuse compared to other controlled substances. However, it stops short of legalizing recreational use.

Once approved, marijuana would be moved from Schedule I to Schedule III, alongside substances like ketamine and some steroids. This follows a recommendation from the Department of Health and Human Services. The process includes a public comment period and administrative review before the final rule is published.

The Attorney General’s office has confirmed the proposal, emphasizing the formal rulemaking process prescribed by Congress in the Controlled Substances Act. President Biden’s support for reviewing federal marijuana laws and pardoning individuals convicted of simple possession aligns with this shift.

The move could boost support for Biden, particularly among younger voters, as public opinion increasingly favors legalization. However, critics argue against the change, citing concerns about marijuana as a “gateway drug” and potential harmful effects.

While rescheduling could ease regulations and reduce tax burdens for the marijuana industry, it poses challenges. Dispensaries would face stricter reporting requirements, and international treaties, like the 1961 Single Convention on Narcotic Drugs, may conflict with the new classification.

Overall, while the DEA’s decision represents a significant departure from past policy, it maintains marijuana’s status as a controlled substance, subject to regulations and restrictions.